The Food and Drug Administration (FDA) conducted an inspection at Bloodworks in Seattle on April 15, focused on blood and blood products, according to information published on the FDA’s website.
The inspection’s final report noted that Bloodworks was not required to make any changes to its operational management.
The FDA conducts regular inspections of facilities nationwide to verify that workplaces and products meet FDA-mandated laws and guidelines aimed at protecting public health. Inspection findings are released for public review.
The FDA’s website states that the agency chiefly oversees the production and distribution of drugs, biological products, medical supplies, and tobacco products for human and animal use to ensure their safety and quality.
Material in this story comes from the U.S. Food and Drug Administration. Source data is available here.
